Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: A case control study

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 751-760

  Arvanitis, Demetrios A ^a   Spandidos, Demetrios A ^b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

CDK; CDKN; Cyclin; Pocket proteins; Retinoblastoma; TP53; TP73

Indexed keywords

CELL MEMBRANE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2D; CYCLIN E; CYCLINE; DIHYDROFOLATE REDUCTASE; ISOPROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN E7; PROTEIN MDM2; PROTEIN P130; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR E2F5; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER GRADING; CARCINOGENESIS; CASE CONTROL STUDY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; EXON; FEMALE; GENE ACTIVATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PHASE TRANSITION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; UPREGULATION; UTERINE CERVIX CANCER;

ADULT; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA, VIRAL; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; S PHASE; UTERINE CERVICAL NEOPLASMS;

EID: 54949116532     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000070     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698, 2000.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ and Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003.
4. Kirnbauer R, Booy F, Cheng N, Lowy DR and Schiller JT: Papillomavirus LI major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89: 12180-12184, 1992.
5. Rose RC, Bonnez W, Reichman RC and Garcea RL: Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67: 1936-1944, 1993.
6. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR and Schiller JT: Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67: 6929-6936, 1993.
7. Skinner SR, Garland SM, Stanley MA, Pitts M and Quinn MA: Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? Med J Aust 188: 238-242, 2008.
8. Goodwin EC and DiMaio D: Repression of human papillo-mavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 97: 12513-12518, 2000.
9. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF and Hagmar B: Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14: 367-372, 2005.
10. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A and zur Hausen H: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314: 111-114, 1985.
11. Klimov E, Vinokourova S, Moisjak E, Rakhmanaliev E, Kobseva V, Laimins L, Kisseljov F and Sulimova G: Human papilloma viruses and cervical tumours: mapping of integration sites and analysis of adjacent cellular sequences. BMC Cancer 2: 24, 2002.
12. Jeon S and Lambert PF: Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 92: 1654-1658, 1995.
13. Jeon S, Allen-Hoffmann BL and Lambert PF: Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 69: 2989-2997, 1995.
14. Dyson N, Howley PM, Munger K and Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retino-blastoma gene product. Science 243: 934-937, 1989.
15. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E and Howley PM: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8: 4099-4105, 1989.
16. Werness BA, Levine AJ and Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
17. Deshpande A, Sicinski P and Hinds PW: Cyclins and cdks in development and cancer: a perspective. Oncogene 24: 2909-2915, 2005.
18. Sherr CJ: Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 107: 181-186, 1995.
19. Stevens C and La Thangue NB: E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 412: 157-169, 203.
20. Cobrinik D: Pocket proteins and cell cycle control. Oncogene 24: 2796-2809, 2005.
21. Cam H and Dynlacht BD: Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 3: 311-316, 2003.
22. Dimova DK and Dyson NJ: The E2F transcriptional network: old acquaintances with new faces. Oncogene 24: 2810-2826, 2005.
23. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005.
24. Lowe SW and Sherr CJ: Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13: 77-83, 2003.
25. Marin MC and Kaelin WG Jr: p63 and p73: old members of a new family. Biochim Biophys Acta 1470: M93-M100, 2000.
26. Lissy NA, Davis PK, Irwin M, Kaelin WG and Dowdy SF: A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407: 642-645, 2000.
27. Yamasaki L: Role of the RB tumor suppressor in cancer. Cancer Treat Res 115: 209-239, 2003.
28. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE and Schiffman M: A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 94: 1406-1414, 2002.
29. Ferenczy A and Franco E: Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 3: 11-16, 2002.
30. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ and Snijders PJ: The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76: 1057-1062, 1995.
31. Arends MJ, Donaldson YK, Duvall E, Wyllie AH and Bird CC: HPV in full thickness cervical biopsies: high prevalence in CIN 2 and CIN 3 detected by a sensitive PCR method. J Pathol 165: 301-309, 1991.
32. Chen KY: Transcription factors and the down-regulation of G1/S boundary genes in human diploid fibroblasts during senescence. Front Biosci 2: D417-D426, 1997.
33. Farkas T, Hansen K, Holm K, Lukas J and Bartek J: Distinct phosphorylation events regulate p130- and p107-mediated repression of E2F-4. J Biol Chem 277: 26741-26752, 2002.
34. Parakati R and Dimario JX: Dynamic transcriptional regulatory complexes including E2F4, p107, p130, and Sp1 control fibroblast growth factor receptor 1 gene expression during myogenesis. J Biol Chem 280: 21284-21294, 2005.
35. Crosby ME and Almasan A: Opposing roles of E2Fs in cell proliferation and death. Cancer Biol Ther 3: 1208-1211, 2004.
36. La Thangue NB: The yin and yang of E2F-I: balancing life and death. Nat Cell Biol 5: 587-589, 2003.
37. Tashiro E, Maruki H, Minato Y, Doki Y, Weinstein IB and Imoto M: Overexpression of cyclin D1 contributes to malignancy by up-regulation of fibroblast growth factor receptor 1 via the pRB/E2F pathway. Cancer Res 63: 424-431, 2003.
38. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK III, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ and Pestell RG: Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20: 672-683, 2000.
39. Hwang HC and Clurman BE: Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786, 2005.
40. Woo RA and Poon RY: Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle 2: 316-324, 2003.
41. Arvanitis DA, Lianos E, Soulitzis N, Delakas D and Spandidos DA: Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. Oncol Rep 12: 1131-1137, 2004.
42. Harms KL and Chen X: The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol 25: 2014-2030, 2005.
43. Nieh S, Chen SF, Chu TY, Lai HC, Lin YS, Fu E and Gau CH: Is pl6(INK4A) expression more useful than human papillo-mavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol 97: 35-40, 2005.
44. Murphy N, Ring M, Heffron CC, King B, Killalea AG, Hughes C, Martin CM, McGuinness E, Sheils O and O'Leary JJ: p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 58: 525-534, 2005.
45. Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, Golovina D, Bliev A, Spitkovsky D, Ermilova V and Kisseljov F: Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 4: 58, 2004.
46. Santin AD, Zhan F, Bignotti E, Siegel ER, Cane S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr and Pecorelli S: Gene expression profiles of primary HPV16-and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 331: 269-291, 2005.
47. Wang JL, Zheng BY, Li XD, Angstrom T, Lindstrom MS and Wallin KL: Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 10: 2407-2414, 2004.
48. Moore GD, Lear SC, Wills-Frank LA, Martin AW, Snyder JW and Helm CW: Differential expression of cdk inhibitors p16, p21cipl, p27kip1, and cyclin E in cervical cytological smears prepared by the ThinPrep method. Diagn Cytopathol 32: 82-87, 2005.
49. Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, Duensing S, Sheets EE, Munger K and Crum CP: Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 25: 884-891, 2001.
50. Wang JL, Zheng BY, Li XD, Nokelainen K, Angstrom T, Lindstrom MS and Wallin KL: p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia. Mod Pathol 18: 629-637, 2005.